Leyden Labs Reports Positive Phase 1 Results for RIG-101, Supporting Advancement into Phase 2 to Protect Asthma Patients

argenx Completes Acquisition of Forte Biosciences, Inc.

Pivoting from prestige to purpose: Paul Peter Tak’s journey to pursue cures

Petra Baarendse vanaf 1 september nieuwe directeur-bestuurder Stichting Utrecht Science Park

Amyl Therapeutics haalt bijkomend € 8,25 miljoen op in Serie A-financieringsronde om baanbrekend platform voor neurodegeneratieve aandoeningen te valideren

Cleara Biotech Secures U.S. and Chinese Patent Protection for its p53-Targeting Development Candidate CL04183

Toxys and Mutagentech Expand Access to Next-Generation Mutation Analysis Through Strategic Collaboration

MAASH secures over €12 million to accelerate its next phase of growth

Revier Therapeutics Launches with €6 Million Seed Financing to Pioneer Class IIa HDAC Inhibitors for Cardiometabolic Disease

Valerio Therapeutics to Acquire Etherna Therapeutics, Strengthening Targeted RNA Platform

From Idea to Impact: Inside Rotterdam’s Life Sciences Ecosystem

BioMarin to Acquire Alesta Therapeutics for Up to $490 Million, Advancing Oral Treatment for Rare Bone Disease Hypophosphatasia

Duurzaam en circulair: grote ambities bij Brecon Cleanroom Systems

Novo Nordisk and AWS Enter Strategic Partnership to Transform Drug Discovery with AI

Althea Stillman on Building Bridges Between Biology, AI, and Business at Biohub

Curium acquirs Abscint SA, expanding PET radiodiagnostic pipeline in oncology

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Bio-Prodict is recognized as the best mutation AI prediction company in the world and secures a large series A investment

‘Logische volgende stap’

Workplace Stress: The Good, The Bad and The Ugly

PHC Europe: Pioneering Innovations in Cell-based R&D process